Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers

Lung Cancer

Volumn 56, Issue 3, 2007, Pages 337-340

  Amachika, Tomoko ^a   Kobayashi, Daisuke ^a   Moriai, Ryosuke ^a   Tsuji, Naoki ^a   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnosis; mRNA expression; Non small cell lung carcinoma; Oncogene; TaqMan RT PCR; Tyrosine kinase

Indexed keywords

MESSENGER RNA; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SAMPLING; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 34247583954     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.01.002     Document Type: Article

References (15)

1. Betticher D.C. Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. Lung Cancer 50 Suppl. 2 (2005) S9-S16
2. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
3. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193-204
4. Hubbard S.R., Mohammadi M., and Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 273 (1998) 11987-11990
5. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
6. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
7. Langer C.J., and Natale R.B. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 32 (2005) S23-S29
8. Buter J., and Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park) 19 (2005) 1707-1711
9. Edelman M.J. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. Semin Oncol 32 (2005) S3-S8
10. Cappuzzo F., Bemis L., and Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354 (2006) 2619-2621
11. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53 (1993) 2379-2385
12. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 (2001) 1850-1855
13. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12 (2006) 710-717
14. Liu L., Yu X.Z., Li T.S., Song L.X., Chen P.L., Suo T.L., et al. A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 64 (2004) 3491-3499
15. Chen Y., Li Y.H., Chen X.P., Gong L.M., Zhang S.P., Chang Z.J., et al. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res 65 (2005) 10838-10846